SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aventus Network

Aventus Network ($AVT) is generating buzz following its DAO's incorporation in the UAE and strategic partnerships enhancing its Aventus Cloud offering, leading the community to discuss a potential breakout driven by its enterprise-grade Polkadot integration, perceived undervaluation, and hopes for increased trading volume and exchange listings.

JFrog Ltd. engages in the provision of an end-to-end, hybrid, universal development operations platform that powers and controls the software supply chain, which enables organizations to continuously and securely deliver software updates across any system. It operates through the following geographical segments: United States, Israel, India, and Rest of World. The firm is also involved in creating software delivered without friction from developer to device. The company was founded by Frederic Simon, Shlomi Ben Haim, and Yoav Landman in 2008 and is headquartered in Sunnyvale, CA.

JFrog Ltd

A notable sell-off in JFrog shares is sparking intense community discussion, with traders debating the implications of Anthropic's new Claude Code Security on the DevSecOps sector, while some analysts view the sharp decline as an exaggerated market reaction.

What are Mirrored Assets? MIR is the governance token of Mirror Protocol, a synthetic assets protocol built by Terraform Labs (TFL) on the Terra blockchain.  Mirror Protocol is decentralized from day 1, with the on-chain treasury and code changes governed by holders of the MIR token. TFL has no intention of keeping or selling MIR tokens, and there are no admin keys or special access privileges granted. The intent for this is to be a completely decentralized, community-driven project.  Mirrored assets are blockchain tokens that behave like ""mirror"" versions of real-world assets by reflecting the exchange prices on-chain. They give traders the price exposure to real assets while enabling fractional ownership, open access and censorship resistance as any other cryptocurrency. Unlike traditional tokens which serve to represent a real, underlying asset, mAssets are purely synthetic and only capture the price movement of the corresponding asset.

Mirror Protocol

Mirror Protocol ($MIR) is trending with a significant price pump, sparking active community speculation about its potential for explosive gains and its strong connection to the Terra ecosystem, as many anticipate its movement often precedes or accompanies a rally in $LUNC.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

The Sweat Economy ($SWEAT) is trending as the community actively discusses its "move-to-earn" utility, with many expressing long-term optimism for its future appreciation despite its current low valuation, while others inquire about acquiring the token.

Synthetix is a decentralized perpetual futures protocol built on Ethereum Mainnet. Synthetix uses a hybrid design — off-chain order matching on a high-performance CLOB with on-chain settlement — to deliver low latency, deep liquidity, and MEV-resistant execution while keeping custody and finality on Ethereum. Traders get CEX-like performance with on-chain security and composability. The protocol’s liquidity is provided by the Synthetix Liquidity Provider (SLP) vault and backstopped by staked SNX collateral, which underwrites the issuance of the sUSD stablecoin and the solvency of the SLP vault.

Synthetix Network 

Synthetix Network is capturing significant attention with its upcoming launch of V3 perpetuals on Ethereum Mainnet and a highly anticipated trading competition, which are fueling bullish community discussions about a potential breakout. Traders are also actively discussing its strategic shift to deflationary tokenomics and focus on institutional-grade derivatives, positioning it as a key player in the evolving DeFi landscape.

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Fortress Biotech Inc - 9.375% PRF PERPETUAL USD 25 - Ser A

Fortress Biotech's preferred shares ($FBIOP) are trending as the FDA approval of CUTX-101 and its associated Priority Review Voucher (PRV) bring anticipated cash flow, prompting community discussion around the reinstatement of suspended dividends and the significant valuation disconnect with its common stock ($FBIO).

PAX Gold (PAXG) is an asset-backed token where one token should represent one fine troy ounce of a London Good Delivery gold bar, stored in professional vault facilities. Anyone who owns PAXG has ownership rights to that gold under the custody of Paxos Trust Company. Since PAXG represents physical gold, its value is tied directly to the real-time market value of that physical gold.  PAXG gives customers the benefits of actual physical ownership of specific gold bars with the speed and mobility of a digital asset. Customers are able to have fractional ownership of physical bars. On the Paxos platform, customers can convert their tokens to allocated gold, unallocated gold, or fiat currency (and vice versa) quickly and efficiently, reducing their exposure to settlement risk. PAXG is also available for trading on Paxos’ itBit exchange. PAXG will also be available on other crypto-asset exchanges, wallets, lending platforms and elsewhere within the crypto ecosystem.   At any time, PAXG holders can lookup the serial number, value and physical characteristics of their vaulted gold just by entering their Ethereum wallet address on the PAXG lookup tool on Paxos.com/paxgold.

PAX Gold

PAX Gold is actively trending as major crypto exchanges increase offerings for tokenized precious metals, driving community discussion around its role as a premier digital gold asset. Investors are increasingly viewing PAXG as a secure, physically-backed safe haven amidst broader market uncertainties and the ongoing debate comparing its stability against traditional gold products and other cryptocurrencies.

Santacruz Silver Mining Ltd. engages in the acquisition, exploration, and development of mineral properties. It operates through the following segments: Bolivar, Porco, Caballo Blanco Group, San Lucas Group, Zimapan, and Corporate and Other. The Bolivar segment focuses on mine and processing plants. The Porco segment is invovled in mine and processing plants. The Caballo Blanco Group segment includes the Tres Amigos, Colquechaquita mines and the Don Diego processing plant. The San Lucas Group segment refers to Reserva mine and San Lucas feed sourcing business. The Zimapan segment consists of mine and processing plant. The company was founded on January 24, 2011 and is headquartered in Vancouver, Canada.

Santacruz Silver Mining Ltd

Santacruz Silver Mining Ltd.

Santacruz Silver Mining Ltd. is trending following its recent Nasdaq uplisting and strong production figures, with the community actively discussing its perceived significant undervaluation and robust growth potential driven by a booming silver market.

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals is trending following FDA approval of EMPAVELI for rare kidney diseases C3G and IC-MPGN, which the community views as a major de-risking event and significant revenue opportunity. This positive news is contrasted with ongoing frustration over management's commercial execution and perceived undervaluation, fueling speculation about a potential buyout.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is trending after the FDA accepted its resubmitted Biologics License Application for RP1 in advanced melanoma, setting an April 2026 decision date. This development has ignited significant optimism for approval and a strong short squeeze, though community discussion reflects ongoing debate regarding the drug's ultimate market success and the FDA's regulatory unpredictability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) has received an average rating of "Moderate Buy" from the thirteen analysts that are covering the stock, MarketBeat Ratings reports. One equities...

Vor Biopharma (NASDAQ:VOR) Stock Price Down 4% - What's Next?

Vor Biopharma (NASDAQ:VOR) Shares Down 4% - Time to Sell...

Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of "Moderate Buy" from Brokerages

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) has received an average recommendation of "Moderate Buy" from the fourteen brokerages that are covering the company, MarketBeat.com reports. One...

Ariose Capital Management Ltd Invests $5.37 Million in Vor Biopharma Inc. $VOR

Ariose Capital Management Ltd acquired a new stake in Vor Biopharma Inc. (NASDAQ:VOR - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities...

Vor Biopharma Target of Unusually High Options Trading (NASDAQ:VOR)

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) was the recipient of some unusual options trading on Friday. Stock traders acquired 4,176 put options on the stock. This is an increase of 196...

Vor Biopharma Inc. (NASDAQ:VOR) Receives Average Rating of "Moderate Buy" from Analysts

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) has earned an average rating of "Moderate Buy" from the thirteen brokerages that are presently covering the stock, Marketbeat reports. One analyst...

Vor Biopharma Inc. (NASDAQ:VOR) Sees Large Growth in Short Interest

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) saw a large increase in short interest during the month of December. As of December 15th, there was short interest totaling 1,943,561 shares, an...

JPMorgan Chase & Co. Issues Pessimistic Forecast for Vor Biopharma (NASDAQ:VOR) Stock Price

JPMorgan Chase & Co. reduced their price objective on shares of Vor Biopharma from $43.00 to $40.00 and set an "overweight" rating for the company in a report on Friday...

Vor Biopharma (NASDAQ:VOR) Earns Buy Rating from Analysts at TD Cowen

TD Cowen started coverage on shares of Vor Biopharma in a research report on Wednesday. They issued a "buy" rating for the company...

Manufacturing Stocks To Keep An Eye On - December 9th

Taiwan Semiconductor Manufacturing, Applied Materials, and Vor Biopharma are the three Manufacturing stocks to watch today, according to MarketBeat's stock screener tool. Manufacturing stocks are...

Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to provide a single company solution for patients suffering from hematological malignancies. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Boston, MA.

Current Price	$13.55
Prev Close	$13.31
Open	$13.27
Dividend Yield	0.00%
50-Day Moving Average	$13.58
Beta	1.06
Avg. Volume	1.08M
PE Ratio	-0.04

52-Week High	$65.80
52-Week Low	$2.62
Market Capitalization	$562.63M
EPS (Annual)	-$34.03
Price to Book	-0.06
Revenue Per Employee	$0.00

VOR
Vor Biopharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VOR News

VORVor Biopharma Inc